EPI-7170
Based on 1 publication(s) in Google Scholar
EPI-7170, a ralaniten analogue, is a potent androgen receptor N-terminal structural domain antagonist that blocks the transcriptional activity of full-length AR (FL-AR) and AR splice variants (AR-Vs). EPI-7170 has antitumor effects against enzalutamide resistant castration-resistant prostate cancer (CRPC).
For research use only. We do not sell to patients.
- Purity: 99.86%
- CAS No.: 2139288-26-7
- Formula: C22H28Cl3NO6S
- Molecular Weight:540.88
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Cancer Compound Library
HY-L025
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Nuclear Receptor Compound Library
HY-L126
-
Anti-Drug-Resistant Compound Library
HY-L169
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) EPI-7170
More
Biological Activity
EPI-7170 (0-12 μM, 24 or 48 h) inhibits cell proliferation in VCaP-ENZR and C4-2B-ENZR cells, also enhances the effect of enzalutamide which has a lower IC 50 when bound to EPI-7170[1].
EPI-7170 (0-20 μM, 24 or 48 h) synergistically inhibits androgen receptor (AR) transcriptional activity in ENZR cells expressing androgen receptor splice variant-7 (AR-V7) with enzalutamide[1].
EPI-7170 (3.5 μM, 48 h) results in an increase in G1 phase and a decrease in S phase, and reduces the expression levels of CDK4, cyclin D1 and cyclin A2 proteins[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:C4-2B-ENZR cells
-
Concentration:3.5 μM
-
Incubation Time:48 h
-
Result:Resulted in an increase in G1 phase and a decrease in S phase, and reduced the expression levels of CDK4, cyclin D1 and cyclin A2 proteins.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:6-8 week old male NOD/SCID mice infected with VCaP-ENZR cells[1]
-
Dosage:30 mg/kg
-
Administration:Oral administration; daily; 31 days
-
Result:Significantly reduced tumor volume and decreased levels of FL-AR and AR-V7 in harvested xenografts.
Chemical Information
-
CAS No. 2139288-26-7
-
Appearance Oil
-
Molecular Weight 540.88
-
Formula C22H28Cl3NO6S
-
Color Colorless to off-white
-
SMILES
CC(C1=CC(Cl)=C(C(Cl)=C1)OC[C@H](O)CCl)(C2=CC=C(C=C2)OC[C@H](O)CNS(C)(=O)=O)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Cell Commun Signal
Emerging role of HIC1 in prostate cancer progression and therapeutic response: A novel perspective. [Abstract]2025 Oct 3;19(4):e12032. PMID: 41050263
Solvent & Solubility
DMSO : 100 mg/mL (184.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8488 mL | 9.2442 mL | 18.4884 mL | 46.2210 mL |
| 5 mM | 0.3698 mL | 1.8488 mL | 3.6977 mL | 9.2442 mL | |
| 10 mM | 0.1849 mL | 0.9244 mL | 1.8488 mL | 4.6221 mL | |
| 15 mM | 0.1233 mL | 0.6163 mL | 1.2326 mL | 3.0814 mL | |
| 20 mM | 0.0924 mL | 0.4622 mL | 0.9244 mL | 2.3110 mL | |
| 25 mM | 0.0740 mL | 0.3698 mL | 0.7395 mL | 1.8488 mL | |
| 30 mM | 0.0616 mL | 0.3081 mL | 0.6163 mL | 1.5407 mL | |
| 40 mM | 0.0462 mL | 0.2311 mL | 0.4622 mL | 1.1555 mL | |
| 50 mM | 0.0370 mL | 0.1849 mL | 0.3698 mL | 0.9244 mL | |
| 60 mM | 0.0308 mL | 0.1541 mL | 0.3081 mL | 0.7703 mL | |
| 80 mM | 0.0231 mL | 0.1156 mL | 0.2311 mL | 0.5778 mL | |
| 100 mM | 0.0185 mL | 0.0924 mL | 0.1849 mL | 0.4622 mL |
Powered by Bioz